TRPharm and CrystalGenomics entered into a licensing agreement for commercialization of CrystalGenomics’ Acelex in Turkey and Middle East & North Africa region
TRPharm and CrystalGenomics announced today a Licensing and Supply Agreement for CrystalGenomics’ Acelex® (polmacoxib). The product, developed by CrystalGenomics, is a next generation COX-2 inhibitor that specifically targets affected joints. Acelex has been approved for the treatment of osteoarthritis in South Korea in February 2015. As a part of this agreement, TRPharm will have the rights to register, manufacture and commercialize in Turkey and MENA region.
Mehmet Göker, General Manager of TRPharm, commented “From the day of its establishment, rheumatology has been one of the key areas of focus for TRPharm. Our target is to not only be with the patient and physician at every step but be a partner for health authorities across the region. We are very happy to be doing this with an esteemed partner such as CrystalGenomics.”
Chairman & CEO of CrystalGenomics, Dr. Joong Myung Cho said, “We are quite pleased with this partnership as it provides us with a great opportunity to penetrate the Turkish and MENA markets with TRPharm, a young pharmaceutical company with a clear vision to become a dominant player within the region with a competitive portfolio of novel therapeutics.”
TRPharm will commence immediately with technology transfer of the product to Turkey. This agreement will be an important component of TRPharm’s ongoing efforts to address patients and physician needs across the whole spectrum of inflammation with its in-licensed and pipeline products. As a result of this agreement, CrystalGenomics will also be extending the reach of this novel therapy.
TRPharm is a pharma start-up focused on innovation with investments into R&D and a cutting edge biotechnological manufacturing capability with the aim of becoming a regional commercial player based out of Turkey.
TRPharm focuses on the launch of new and innovative medicines starting from registration and accomplishment of clinical programs in all phases, as well as building a biotech manufacturing facility in Turkey for the supply of monoclonal antibodies to CIS and MENA region besides the local market. TRPharm has a wide product portfolio, led by oncology, virology, inflammatory and rare diseases.
For more information: www.trpharm.com
CrystalGenomics Inc. is a commercial stage biopharmaceutical company focused in the discovery and development of novel drugs in therapeutic areas of unmet medical needs including inflammation, oncology, and infectious disease.
For more information, please visit: www.cgxinc.com.